Trial · NCT02012192
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
NCT02012192, Phase 1, Phase 2, Terminated, Medical University Innsbruck; results first posted 2019-08-13
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer. Trials, record NCT02012192. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02012192
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
- NCT number
- NCT02012192
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 133 participants, actual
- Lead sponsor
- Medical University Innsbruck
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Interventions
- Ganetespib, Paclitaxel
- First posted
- 2013-12-16
- Last updated
- 2019-08-13
- Other registries' IDs
- eudract:2013-003868-31
- Results first posted
- 2019-08-13
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | Time until progression (median w/o new drug 4 months) | evaluate the efficacy of ganetespib in combination with weekly paclitaxel compared to weekly paclitaxel alone as measured by Progression-free survival (PFS). Response or progression will be evaluated in this study according to Response Evaluation Criteria In Solid Tumors Criteria version 1.1., CA-125 according to published GCIG criteria, and by the investigator on the basis of physical and/or gynaecological examinations. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression Free Survival (PFS) | Time until progression (median w/o new drug 4 months) | ITT population | months | MEDIAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression Free Survival (PFS) | Ganetespib + Paclitaxel | 3.5 | 95% Confidence Interval 3.092 to 3.882 | months | |
| Progression Free Survival (PFS) | Paclitaxel | 5.3 | 95% Confidence Interval 4.006 to 6.652 | months |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Ganetespib + Paclitaxel | 90 | |
| Overall Study | STARTED | Paclitaxel | 43 | |
| Overall Study | COMPLETED | Ganetespib + Paclitaxel | 63 | |
| Overall Study | COMPLETED | Paclitaxel | 43 | |
| Overall Study | NOT COMPLETED | Ganetespib + Paclitaxel | 27 | |
| Overall Study | NOT COMPLETED | Paclitaxel | 0 |
Source ClinicalTrials.gov
Adverse events202
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Ganetespib + Paclitaxel | 56 | 90 | |
| other | Anemia | Blood and lymphatic system disorders | Paclitaxel | 27 | 43 | |
| other | Abdominal pain | Gastrointestinal disorders | Ganetespib + Paclitaxel | 31 | 90 | |
| other | Abdominal pain | Gastrointestinal disorders | Paclitaxel | 12 | 43 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Ganetespib + Paclitaxel | 7 | 90 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Paclitaxel | 0 | 43 | 0 |
| other | Abdominal distention | Gastrointestinal disorders | Ganetespib + Paclitaxel | 8 | 90 | |
| other | Abdominal distention | Gastrointestinal disorders | Paclitaxel | 2 | 43 | |
| other | Constipation | Gastrointestinal disorders | Ganetespib + Paclitaxel | 21 | 90 | |
| other | Constipation | Gastrointestinal disorders | Paclitaxel | 9 | 43 |
1 to 10 of 202Source ClinicalTrials.gov
See all 202 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Ganetespib + Paclitaxel | 66 | 90 |
| Total, all-cause mortality | Paclitaxel | 29 | 43 |
| Total, other adverse events | Ganetespib + Paclitaxel | 88 | 90 |
| Total, other adverse events | Paclitaxel | 41 | 43 |
| Total, serious adverse events | Ganetespib + Paclitaxel | 34 | 90 |
| Total, serious adverse events | Paclitaxel | 10 | 43 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Ganetespib + Paclitaxel vs Paclitaxel: deaths from any cause | Trial comparisons |
| Ganetespib + Paclitaxel vs Paclitaxel: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02012192
GET https://conductscience.org/api/trials/v1/NCT02012192/events?page=2